I guess we can only go with what information we have been given, and I am none the wiser. They did however mention there would be two interm read-outs on the Phase 3 CHF trials. It is the second interim read-out that is going to test for futility and overwhelming efficacy.
We have a relatively good idea on the first interim read-out (Q2), but the second interim read-out could come at any time - as it is an event driven trigger i.e. when approx. 50% events occur, they will un-blind and crunch the numbers. If it shows that a pre-determined efficacy threshold has been met, then they stop the trial and we can pop the champagne!
None of this has been formally detailed in an ASX announcement, so we are going off what we have heard from conferences and shareholder meetings.
In any case, there is no denying that we are getting close to the pointy end of the run-way. And that is something to get excited about
$5.8 Billion, page-37
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |